Events - Event View

$5 - $10 Suggest donation for non-members

Exciting advances in medical science are changing the way we think about cancer detection. Multi-cancer early detection tests aim to identify multiple types of cancer—sometimes before symptoms appear—using a simple blood sample. But how accurate are they? Who should consider them? And what questions still remain? We are honored to welcome Dr. Ruth Etzioni to speak on this impactful area of research. Join us for an informative discussion about the promise, the limitations, and what these emerging tools could mean for the future of cancer screening.
Ruth Etzioni, PhD is a biostatistician specializing in cancer screening and early .
detection, with a focus on prostate and breast cancer. She develops methods to evaluate diagnostic tests, builds models to understand how screening affects cancer incidence and mortality, and studies the costs, benefits, and potential overdiagnosis associated with screening. She also evaluates emerging cancer biomarkers, tracks patterns in cancer care, and leads the biostatistics core for the National Cancer Institute–funded Northwest Prostate Cancer SPORE. Throughout her work, she is committed to reducing health disparities and improving outcomes